[Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].

Abstract

Treatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson's disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.

• Authors: Charlotte Steffensen, Merete Lund Mægbæk, Peter Laurberg, Marianne Andersen, Caroline Kistorp, Helene Nørrelund, Jakob Dal, Jens Otto Lunde Jørgensen
• Journal: Ugeskrift for laeger (Ugeskr Laeger) Vol. 176 Issue 1 Pg. 58-60 (01 06 2014) ISSN: 1603-6824 [Electronic] Denmark
• Vernacular Title: Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinæmi.
• PMID: 24629610 (Publication Type: Journal Article, Review)

Chemical References

• Antiparkinson Agents
• Dopamine Agonists
• Ergolines
• Cabergoline

Topics

• Antiparkinson Agents (administration & dosage, adverse effects, therapeutic use)
• Cabergoline
• Dopamine Agonists (administration & dosage, adverse effects, therapeutic use)
• Ergolines (administration & dosage, adverse effects, therapeutic use)
• Heart Valve Diseases (chemically induced, diagnostic imaging, physiopathology)
• Humans
• Hyperprolactinemia (diagnostic imaging, drug therapy)
• Parkinson Disease (drug therapy)
• Ultrasonography